Jump to content

Template:Published case reports of cyproterone acetate-associated meningioma

Add links
From Wikipedia, the free encyclopedia
Published case reports of cyproterone acetate-associated meningioma
# Age Sex Medications Treatment
duration		 Ref Link
1 28 years MtF CPA 100 mg/day, EE 100 μg/day 5 years Gazzeri et al. (2007) [1]
2 48 years MtF CPA 100 mg/day, EE ("feminizing regimen") 10 years Cebula et al. (2010) [2]
3 46 years Female CPA 50 mg/day, E2 ("substitutive") 10 years Gonçalves et al. (2010) [3]
4 83 years Male CPA ≥50 mg/day 2 years Gil et al. (2011) [4]
5 71 years Male CPA ≥50 mg/day 3 years Gil et al. (2011) [4]
6 66 years Female CPA ≥50 mg/day 3 years Gil et al. (2011) [4]
7 43 years Female CPA ≥50 mg/day 2 years Gil et al. (2011) [4]
8 35 years MtF CPA 100 mg/day, E2 100 μg/day patch 4 years Bergoglio et al. (2012) [5]
9 60 years MtF CPA 50 mg/day, E2 8 mg/day oral 10 years Knight et al. (2013) [6]
10 56 years MtF CPA, EV 2 mg/day oral 8 years Razavi (2014) [7]
11 51 years Female CPA 15 mg/day 30 years Bernat et al. (2015) [8]
12 47 years Female CPA 25 mg/day 15 years Bernat et al. (2015) [8]
13 43 years Female CPA 50 mg/day 12 years Bernat et al. (2015) [8]
14 39 years Female CPA 50 mg/day 10 years Bernat et al. (2015) [8]
15 61 years Female CPA 25 mg/day 24 years Bernat et al. (2015) [8]
16 38 years Female CPA 25 mg/day 10 years Bernat et al. (2015) [8]
17 45 years Female CPA 50 mg/day 20 years Bernat et al. (2015) [8]
18 53 years Female CPA 50 mg/day 20 years Bernat et al. (2015) [8]
19 56 years Female CPA 50 mg/day 8 years Bernat et al. (2015) [8]
20 55 years Female CPA 50 mg/day 30 years Bernat et al. (2015) [8]
21 49 years Female CPA 50 mg/day 20 years Bernat et al. (2015) [8]
22 49 years Female CPA 50 mg/day 25 years Bernat et al. (2015) [8]
23 58 years Female CPA 50 mg/day 18 years Botella et al. (2015) [9]
24 37 years Female CPA 50 mg/day 11 years Botella et al. (2015) [9]
25 42 years Male CPA 100 mg/day 23 years Sys & Kestelyn (2015) [10]
26 45 / 46 years MtF CPA 10 or 100 mg/day, E2 20 mg/4 months implant 5 years ter Wengel et al. (2015) [11][12]
27 51 years MtF CPA 100 mg/day, EE 100 μg/day 25 years ter Wengel et al. (2015) [11][12]
28 65 years MtF CPA 10 mg/day, CEEs 1.25 mg/day 19 years ter Wengel et al. (2015) [11][12]
29 26 years Female CPA 50 mg/day 10 years Kalamarides & Peyre (2017) [13]
30 43 years Female CPA 25 mg/day 25 years Kalamarides & Peyre (2017) [13]
31 83 years Male CPA 200 mg/day 7 months Keilani & Abada (2017) [14]
32 65 years Female CPA 50 mg/day 15 years Bernat et al. (2018) [15]
33 77 years MtF CPA 50 mg/day, E2 50 μg/day patch 24 years Boer et al. (2018) [16]
34 41 years MtF CPA 50 mg/day, E2 gel 1–3 mg/day 9 years Mancini et al. (2018) [17]
35 60 years MtF CPA, CEEs 36 years Nizar & Seal (2018) [18]
36 51 years MtF CPA 20 mg/week, E2 100 μg/day patch 11 years Nota et al. (2018) [12]
37 66 years MtF CPA 10 mg/day 40 years Nota et al. (2018) [12]
38 58 years MtF CPA 50 mg/day, E2 100 μg/day patch 6 years Nota et al. (2018) [12]
39 49 years MtF CPA, EV 2 mg/day 16 years Nota et al. (2018) [12]
40 51 years MtF CPA 100 mg/day, EE 100 μg/day patch 26 years Nota et al. (2018) [12]
41 50 years MtF CPA 50 mg/day, E2 0.6 mg/g cream 2x/day ~10 years Raj et al. (2018) [19]
42 48 years MtF CPA 50 mg/day, E2 1 mg/g cream 3x/day 21 years Raj et al. (2018) [19]
43 43 years Female CPA 25–50 mg/day, EV 2 mg/day, finasteride 5 mg/day, others 23 years Chasseur et al. (2019) [20]
44 67 years MtF CPA, estrogen >14 years Alalade et al. (2019) [21]
45 46 years Female CPA 5 mg/day, subsequently NOMAC 5 mg/day 15 years Champagne et al. (2019) [22]
46 58 years Female CPA 25–100 mg/day for 10 days/cycle 34 years Owens et al. (2019) [23]
47 ? Male CPA 300 mg/2 weeks i.m., leuprorelin 11.25 mg/3 months i.m. ? Colstrup et al. (2020) [24]
Abbreviations: CPA = Cyproterone acetate. E2 = Estradiol. EV = Estradiol valerate. CEEs = Conjugated estrogens. EE = Ethinylestradiol. MtF = Male-to-female (transgender woman). Notes: For the Bernat et al. (2015) cases, only one was reported to be taking an estrogen (specifically estradiol).[8] Froelich et al. (2008) reported an additional 8 female cases (age 33–62 years, mean 46 years; 50 mg/day CPA; 10–20 years exposure) with multiple meningiomas.[25] Cea-Soriano et al. (2012) also reported 8 cases (4 male (≥50 mg/day, ORTooltip odds ratio = 3.28), 4 female (2 mg/day, OR = 1.03)) with no individual specifics.[9][26] Peyre et al. reported 38 operated cases.[27] Portet et al. (2019) reported 30 operated cases.[28] Cases in association with other progestins have been reported as well.[8] Deipolyi, Han, & Parsa (2010) reported a case in an MtF in association with E2 100 μg/day only.[29] Sources: [11][17][30]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Template:Published_case_reports_of_cyproterone_acetate-associated_meningioma&oldid=1199168430"